Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Nang Kuang Pharmaceutical Co EV-to-EBITDA?
Nang Kuang Pharmaceutical CoTPE:1752 -0.31%92 EV-to-EBITDA is 8.10 as of Aug. 26, 2026, which is 12% below its 10-year median of 9.24. GuruFocus rates TPE:1752 with a GF Score™ of 92/100 and a GF Value™ of NT$40.89 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 521 Medical Devices & Instruments companies, Nang Kuang Pharmaceutical Co ranks better than 73.7% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Nang Kuang Pharmaceutical Co's enterprise value is NT$3,505 Mil.
Nang Kuang Pharmaceutical Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was NT$432 Mil. Therefore, Nang Kuang Pharmaceutical Co's EV-to-EBITDA for today is 8.10.
The historical rank and industry rank for Nang Kuang Pharmaceutical Co's EV-to-EBITDA or its related term are showing as below:
TPE:1752'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 7.21 Med: 9.24 Max: 17.23
Current: 8.1
During the past 13 years, the highest EV-to-EBITDA of Nang Kuang Pharmaceutical Co was 17.23. The lowest was 7.21. And the median was 9.24.
TPE:1752's EV-to-EBITDA is ranked better than 73.7% of 521
companies
in the Medical Devices & Instruments industry
Industry Median: 14.67
vs TPE:1752: 8.10
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Nang Kuang Pharmaceutical Co (TPE:1752) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Nang Kuang Pharmaceutical Co's PE Ratio (TTM) for today is calculated as:
Nang Kuang Pharmaceutical Co's share price for today is NT$31.70.
Nang Kuang Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$2.020.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:1752 vs ISRG, BDX, MDLN: EV-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, Nang Kuang Pharmaceutical Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nang Kuang Pharmaceutical Co EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Nang Kuang Pharmaceutical Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Nang Kuang Pharmaceutical Co's EV-to-EBITDA falls into.
Nang Kuang Pharmaceutical Co's current Enterprise Value is NT$3,505 Mil.
Nang Kuang Pharmaceutical Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$432 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nang Kuang Pharmaceutical Co (TPE:1752) has a EV-to-EBITDA of 8.10 as of Aug. 26, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Nang Kuang Pharmaceutical Co. This is 12% below median its historical median of 9.24. Over the past decade, Nang Kuang Pharmaceutical Co's EV-to-EBITDA has ranged from 7.21 to 17.23. According to the industry distribution chart, Nang Kuang Pharmaceutical Co ranks #137 out of 521 companies in the Medical Devices & Instruments industry, placing it in the top 26.3%.
Is Nang Kuang Pharmaceutical Co's EV-to-EBITDA too high?
Nang Kuang Pharmaceutical Co's current EV-to-EBITDA of 8.10 is 12% below median its 10-year median of 9.24. Over the past 10 years, this metric has ranged from a low of 7.21 to a high of 17.23. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.67. Nang Kuang Pharmaceutical Co's value of 8.10 is 44.8% below this industry median. Based on the distribution chart, Nang Kuang Pharmaceutical Co ranks #137 out of 521 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Nang Kuang Pharmaceutical Co has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Nang Kuang Pharmaceutical Co's EV-to-EBITDA compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Nang Kuang Pharmaceutical Co ranks #137 out of 521 companies for EV-to-EBITDA. This puts Nang Kuang Pharmaceutical Co in the upper half of its industry. The industry median EV-to-EBITDA is 14.67. Nang Kuang Pharmaceutical Co's value of 8.10 is 44.8% below this benchmark. Historically, Nang Kuang Pharmaceutical Co's own EV-to-EBITDA has ranged from 7.21 to 17.23 over the past decade. While the company's 10-year median is 9.24 vs. the industry median of 14.67, Nang Kuang Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.67, based on 521 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nang Kuang Pharmaceutical Co's current EV-to-EBITDA of 8.10 is 44.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Nang Kuang Pharmaceutical Co. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nang Kuang Pharmaceutical Co's current EV-to-EBITDA is 8.10, which is 12% below median its own 10-year median of 9.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nang Kuang Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Nang Kuang Pharmaceutical Co (TPE:1752) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$40.89, compared to a current price of NT$31.70 — trading 22.5% below its estimated fair value. The current EV-to-EBITDA is 8.10, which is 12% below median its 10-year median of 9.24 and 44.8% below the Medical Devices & Instruments industry median of 14.67. Nang Kuang Pharmaceutical Co's overall GF Score™ is 92/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Nang Kuang Pharmaceutical Co (TPE:1752), the current EV-to-EBITDA is 8.10 as of Aug. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nang Kuang Pharmaceutical Co (TPE:1752) Overvalued in 2026?
Based on GuruFocus' analysis, Nang Kuang Pharmaceutical Co stock appears to be undervalued.
The current stock price of NT$31.70 is trading 22.5% below its estimated GF Value™ of NT$40.89.
GuruFocus considers Nang Kuang Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for TPE:1752:
EV-to-EBITDA: 8.10 (12% below median its 10-year median of 9.24)
GF Value™: NT$40.89 vs. price of NT$31.70 (22.5% below fair value)
Industry Position: 44.8% below the Medical Devices & Instruments median (#137 of 521)
No single metric tells the full story. See the TPE:1752 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nang Kuang Pharmaceutical Co Ltd is a Taiwan-based company, its subsidiaries are engaged in the manufacture, processing, and trading, and import and export of pharmaceuticals and medical devices. Its products are Cardiovascular system medications, Gastrointestinal medications, Nervous system drugs, Nutrition and Metabolism, Hospital infusion solution, blood products, Anticancer immunomodulators, Musculoskeletal system, and Others. Geographically, the company operates in Taiwan, China, Japan, the USA, and Other countries.
92GF Score
Get the complete analysis for TPE:1752
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1752 has been successfully added to your 
